[Results of treatment with oral anticoagulants in patients with lower limb deep vein thrombosis]. / Rezul'taty lecheniia peroral'nymi antikoaguliantami patsientov s trombozami glubokikh ven nizhnikh konechnostei.

Analysed herein is the incidence rate of decompensated forms of venous insufficiency in patients who endured lower limb deep vein thrombosis and were prescribed either warfarin, rivaroxaban in therapeutic doses or rivaroxaban in a preventive dose. The study enrolled a total of 129 patients presenting with thrombotic lesions of deep veins of the lower limbs. The patients were divided into three groups depending on the anticoagulant therapy prescribed. Patients of the first and second groups for 6 months received warfarin and rivaroxaban, respectively, in therapeutic doses, and group three patients continued taking rivaroxaban in a therapeutic dose for a long time. RESULTS: Eighteen (36%) patients from the first group and two (4.5%) patients from the second group discontinued taking the anticoagulant before the scheduled date. Relapses of venous thromboembolic complications were observed in 11 (22%) group one patients and in 7 (15.9%) group two patients, with no relapses observed in the third group. Negative dynamics of the ultrasonographic picture was observed in two groups: 16% of group one patients and 9.1% of group two patients were found to develop signs of damage of previously unaltered veins or occlusion of a previously patent vein after endured thrombosis without clinical manifestation. Trophic disorders were observed in a third of patients of the first group and in one patient of the second group by the fourth year of follow up. None of the third group patients developed trophic ulcers. Statistically significant differences in the examined groups were obtained for such parameters as adherence to treatment and the degree of severity of venous insufficiency, in favour of rivaroxaban, with quality of recanalization being significantly better in the third group. A conclusion was drawn that prolonged preventive administration of new oral anticoagulants did not lead to the development of decompensated forms of venous insufficiency.

[Contemporary data on efficacy of anticoagulant therapy in recanalization of deep veins]. / Sovremennye dannye ob éffektivnosti antikoaguliantnoi terapii pri rekanalizatsii glubokikh ven.

The article is a literature review containing a detailed description of anticoagulant therapy variants, their efficacy in recanalization of deep veins, as well as patients' compliance to treatment. Russian specialists have demonstrated that the processes of active re-organization of thrombotic masses, in some cases leading to complete clearing of the vessel's lumen from a thrombus, may be observed at terms from 3 to 6 months, with a failure to occur within the above period reportedly followed by formation of irreversible cicatricial-sclerotic alterations in the veins. That is why adequate anticoagulant therapy should be initiated promptly in order to prevent the development of irreversible alterations and a decompensated form of chronic venous insufficiency. The process of recanalization of the venous segments involved appears to primarily depend on efficacy of anticoagulant therapy. Of special attention is a class of novel oral anticoagulants characterised by high clinical efficacy, prolonged and relatively safe administration, as well as thrombolytic activity. The use of anticoagulant therapy, as well as adherence of patients to treatment make it possible to significantly decrease the frequency of a decompensated form of venous insufficiency and the need for reconstruction of the major veins.

[Pathogenesis and prevention of venous and arterial thromboembolic events in patients after deep vein thrombosis of lower extremities]. / Patogenez i profilaktika venoznykh i arterial'nykh tromboémbolii u bol'nykh, perenesshikh tromboz glubokikh ven nizhnikh konechnostei.

AIM: To define the role of thrombophilic and other procoagulant conditions in pathogenesis of deep vein thrombosis and the effectiveness of pathogenetic secondary prevention of venous and arterial thromboembolic events. MATERIAL AND METHODS: The study included 107 patients for the period 2007-2016 who were divided into 3 groups. The main group (n=40) - lifelong individual antithrombotic therapy with warfarin predominantly; the second (control) group (n=39) - warfarin administration for 3-6 months; the third (additional) group (n=28) - specific life-long therapy depending on procoagulant status which was assessed according to original scale. The main anticoagulants were rivoroxaban or dabigatran etexilate. Recurrent venous thromboembolic complications (RVTE) were observed in one (2.5%) patient of the first group and in 8 (20.5%) cases of the second group. In the third group RVTE were absent (significant differences, p<0.03 and 0.001, respectively). Arterial thromboembolic diseases were noted in 1 (2.5%) patient of the first group, in 4 (10.25%) cases of the second group and in none of the third group (significantly only for group II vs. group III, p<0.01). RESULTS: Individual antithrombotic therapy reduces the incidence of recurrent venous and arterial thromboembolic events in patients with idiopathic deep vein thrombosis.